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J PChronic non-communicable diseases (NCDs) cause the majority of premature deaths, disability, and
healthcare expenditures in the U.S. Six largely modiﬁable risk behaviors and factors (tobacco use,
poor nutrition, physical inactivity, alcohol abuse, drug abuse, and poor mental health) account for
more than 50% of premature mortality and considerably more morbidity and disability. The IOM
proposed that population burden of disease and preventability should be major determinants of the
amount of research funding provided by the U.S. NIH. Data on NIH prevention funding between
ﬁscal years 2010 and 2012 for human behavioral interventions that target the modiﬁable risk factors
of NCDs were analyzed during 2013–2014. The NIH prevention portfolio comprises approximately
37% human behavioral studies and 63% basic biomedical, genetic, and animal studies. Approx-
imately 65% of studies were secondary prevention versus 23% for primary prevention, and 71% of
studies intervened at the individual and family levels. Diet and exercise were the most-studied risk
factors (41%), and few studies conducted economic analyses (12%). NIH spends an estimated $2.2–
$2.6 billion annually (7%–9% of the total of $30 billion) on human behavioral interventions to
prevent NCDs. Although NIH prevention funding broadly aligns with the current burden of disease,
overall funding remains low compared to funding for treatment, which suggests funding misalign-
ment with the preventability of chronic diseases.
(Am J Prev Med 2015;48(4):462–471) & 2015 American Journal of Preventive Medicine. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).IntroductionThe burden of largely preventable non-comm-unicable chronic diseases (NCDs) in the U.S. isresponsible for a disproportionate share of mor-
tality, morbidity, and healthcare costs. Annually, seven of
ten deaths are due to NCDs, and treating people with
chronic conditions currently accounts for approximately
84% of annual healthcare expenditures ($2.7 trillion in
2011, or 17.9% of U.S. gross domestic product).1–7
Medical costs are driven by NCDs at all ages, yet 67%
of healthcare dollars are spent on treating NCDs among
working adults aged o65 years.4 The U.S. Burden of
Disease study6 showed that adult men and women
increased their life expectancy between 1990 and 2010;
however, despite these gains there has been a fastererican Heart Association (Calitz); Department of Health
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open access article under the CC BY-NCincrease in years lived with disability. Five modiﬁable risk
behaviors—tobacco use, poor diet, physical inactivity,
alcohol abuse, and drug abuse—are responsible for the
majority of deaths and premature mortality in the U.S.6–9
Increasing rates of mental health disorders are also
contributing toward greater disability, for which there
are few successful interventions.10 These risk factors also
contribute substantially to the observed disparities in life
expectancy and mortality rates between population
groups.11–13 The U.S. has the largest per capita healthcare
expenditures of all other industrialized nations, yet it
consistently ranks near the bottom in preventable
health outcomes compared with other high-income
countries.14 Furthermore, national healthcare costs are
heavily skewed toward prescription drugs, medical devi-
ces, and clinical services, with public health and pre-
vention activities accounting for only 3% of annual
spending.4
The IOM proposed that population burden of disease
and preventability should be major determinants of
priorities for public health interventions and the amount
of research funding provided by the NIH.15,16 Four
barriers related to health research and development
result in signiﬁcant missed opportunities to improvernal of Preventive Medicine  Published by Elsevier Inc. This is an
-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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promotion: (1) persistent knowledge gaps about speciﬁc
cost-effective prevention policies and programs; (2) the
full potential of behavioral economics has not been
realized; (3) lack of effective dissemination strategies
for different population groups and implementation
settings; and (4) where robust evidence exists, an absence
of comprehensive dissemination.17,18 Limited empirical
data on these barriers fuel the protracted debate about
whether prevention and preventive health services save
money and represent good investments.19–22 Until
recently, the Congressional Budget Ofﬁce (CBO) ques-
tioned the value of prevention, scoring it low in federal
funding decisions.23 However, the CBO has since sup-
ported some prevention strategies, such as a sharp
increase in federal tobacco taxes,24 and called for better
evidence on how interventions targeting risk factors
might reduce long-term cost increases.25 Estimates
suggest that approximately 50% of NCDs are preventable
by modifying the major risk behaviors and an additional
20%–30% by addressing the social and environmental
determinants of health.6–9 Consequently, improving
population health will require comprehensively imple-
menting effective evidence-based programs and policies
that target these determinants of health and can be
sustained by public–private partnerships.17,26,27Figure 1. Average annual NIH funding for prevention (FY2010–
Source: reportnih.gov/categorical_spending.aspx; authors’ analysis.
Note: Percentages based on grants coded as Prevention by Research Conditi
on annual spending, not number of grants. Other ICs include the remaining
FY, ﬁnancial year; IC, institutes and centers; NCI, National Cancer Institute
Heart Lung and Blood Institute; NIA, National Institute on Aging; NIAAA, Nation
Allergy & Infectious Diseases; NICHD, National Institute of Child Health D
Institute of Diabetes and Digestive and Kidney Diseases; NIEHS, National
Mental Health; NINDS, National Institute of Neurological Disorders and Stro
April 2015The NIH is the world’s largest funder of biomedical
research and receives approximately 90% ($30 billion) of
the $34 billion annual U.S. federal health research and
development budget.28,29 The scale, structure, and prior-
ities of NIH funding have a signiﬁcant impact on
research universities with medical schools and the career
development of research scientists. More than 80% of the
NIH budget funds extramural grants, which support
around 350,000 scientists at 2,500 universities across the
U.S. and around the world.29–31 The NIH estimates that
it spent roughly $6 billion in ﬁscal year (FY) 2012—
almost 20% of total annual expenditures—on prevention
research, including infectious disease prevention.32
Figure 1 summarizes data from Appendix Table 1 and
shows the distribution of all grants coded as Prevention
by the NIH between FY2010 and FY2012. Based on
average award value, the National Institute of Allergy and
Infectious Diseases is the largest funder of prevention
research (24.6%) followed by the National Cancer
Institute (18.9%); both of these Institutes spend more
than $1 billion annually on prevention research
(Appendix Table 1).
The purpose of this research was to characterize NIH
prevention funding according to a variety of prevention
attributes and assess whether the current portfolio is
aligned with the U.S. burden of disease and the majorFY2012).
on and Disease Categorization (RCDC) algorithm. Mean proportion based
13 Institutes and Centers.
; NHGRI, National Human Genome Research Institute; NHLBI, National
al Institute on Alcohol Abuse and Alcoholism; NIAID, National Institute of
evelopment; NIDA, National Institute on Drug Abuse; NIDDK, National
Institute of Environmental Health Services; NIMH, National Institute of
ke.
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and costly NCDs—cancer, coronary heart disease, hyper-
tension, stroke, diabetes, and obesity. Consequently, data
were analyzed from eight Institutes and Centers (ICs)
that are signiﬁcant funders of NCD prevention: the
National Cancer Institute, National Heart Lung and
Blood Institute, National Institute of Child Health
Development, National Institute of Diabetes and Diges-
tive and Kidney Diseases, National Institute of Mental
Health, National Institute of Drug Abuse, and National
Institute on Alcohol Abuse and Alcoholism. Together,
these ICs comprise 55% of annual prevention research
funded between FY2010 and FY2012 (Figure 1). Previous
studies on NIH prevention funding have focused on
single diseases, analyzed data from a small sample of ICs
or short time frames, or compared overall NIH funding
levels for speciﬁc disease conditions with the U.S. burdenDATA DOWNLOADED
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Calitz et al / Am J Prev Med 2015;48(4):462–471 465Studies”) (described further in the Data Selection section). Early
drafts of this manuscript were shared with NIH representatives.
The NIH developed the Research, Condition, and Disease Cate-
gorization (RCDC) process in 2006, which organizes research
funding annually into 235 categories, including a category for
Prevention. RCDC is a computer algorithm based on category
boundaries that are validated by testing assigned projects against
the experts’ consensus of the types of projects that belong in the
category. Given the difﬁculty of conducting portfolio analysis, the
complexity of the RePORTER database, and the fact that the
RCDC algorithm is not openly available to the public without a
Freedom of Information Act (FOIA) request, extensive consulta-
tion with an NIH representative from one IC was used to reﬁne
keyword search terms. A FOIA request was not made at the start of
data coding and analysis owing to perceived time delay. Thus, to
identify research projects potentially not captured by the algorithm
and to test the sensitivity of the current algorithm, studies from
22 relevant disease-speciﬁc RCDC categories (e.g., cancer) and
non-disease RCDC categories (e.g., behavioral science) were
extracted (Figure 2). Numbers were assigned to the three categories
(1¼Prevention RCDC, 2¼Non-disease RCDCs, 3¼Disease-spe-
ciﬁc RCDCs), and Categories 2 and 3 were combined (“Other
RCDCs”) because of the small sample in Category 2 (n¼108). To
limit the sample to prevention research and the NCDs of interest,
the following relevant keywords were used:
Disease-speciﬁc RCDCs—Obesity prevention or cancer preven-
tion or diabetes prevention or hypertension prevention or
coronary heart prevention or stroke prevention or chronic
disease prevention or health promotion or health education or
primary prevention or secondary prevention.
Non-disease RCDCs—Chronic disease prevention or health
promotion or health education or primary prevention or
secondary prevention or behavioral modiﬁcation or intervention
program or lifestyle modiﬁcation.
Although environmental factors are important determinants of
health, they were excluded because of the large anticipated
sample size.
Data Selection
Data were retrieved in July 2013 from eight of 27 ICs, and
information on project number, project title, ﬁnancial year, award
amount, and Administrative IC was extracted. Searches were
restricted to domestic extramural Research Project Grants because
these types of grants comprise the majority of NIH funding.29
Projects funded in FY2010 by the American Recovery and
Reinvestment Act were excluded, which would otherwise have
inﬂated the results for that year. Initial extraction yielded 7,898
projects; de-duplication, giving priority to the Prevention RCDC
grants, yielded 4,305 unique projects and 3,593 duplicates
(Figure 2). A total of 559 projects were excluded and 2,015
projects comprised basic biomedical, animal, and genetic studies
(Non-Behavioral Studies), leaving 1,731 abstracts meeting the
inclusion criteria of domestic human trial interventions aimed at
preventing NCDs and promoting healthy behaviors related to
tobacco, diet, physical activity, alcohol, drugs, and mental health
(Behavioral Studies) (Appendix Table 2). Non-Behavioral Studies
were retained for comparison with Behavioral Studies in terms ofApril 2015number of awards and award amount. Interventions that studied
other risk factors or determinants of health (e.g., SES) were
included and coded as “Other.” Public health surveillance studies
that were not speciﬁcally aimed at preventive interventions were
excluded; however, speciﬁc statistical and economic studies linked
to prevention or speciﬁc risk factors were included and coded
according to risk factor. These included economic studies, for
example, that investigated the effects of price or price elasticity of
demand for tobacco and sugar-sweetened beverages on consump-
tion behavior. Using title and abstract keyword review, one author
excluded studies that did not meet the inclusion criteria and a
second author independently assessed the exclusions. Differences
were reconciled by discussion and consensus (inter-rater reliabil-
ity, 92%–98%).
Data Coding and Analysis
Data were analyzed in 2013–2014. Two authors independently
and manually assessed abstracts of the Behavioral Studies
(n¼1,731) and coded them according to ﬁve dimensions:
prevention type, scope, setting, modiﬁable risk behaviors, and
economic analysis. For prevention setting, a category for “tech-
nology” was included, which comprised interventions that were
designed to be solely delivered via Internet, electronic voice, or
mobile platforms. Data were entered into a database (Microsoft
Excel, version 2011, Microsoft Corporation, Redmond WA) and
differences were reconciled by discussion and consensus (inter-
rater reliability, 82%–84%). Excel data were imported into Stata,
version 12, and analyzed. Descriptive statistics were used to
calculate counts, frequencies, and means. Pearson chi-square
tests were used to assess annual variations for categorical
variables. For continuous variables, ANOVA and paired t-tests
assessed the statistical signiﬁcance between observed differences
in means.
Results
Overview
There were no statistically signiﬁcant variations across
FYs for all coded characteristics apart from Adminis-
trative IC; thus, only mean annual data are reported. The
selected sample comprised an estimated $647 million in
annual prevention funding: $277 million (43%) for
Behavioral Studies and $370 million (57%) for Non-
Behavioral Studies (Table 1). When Other RCDC proj-
ects were excluded (i.e., the sample contained only what
the NIH currently classiﬁes as Prevention), the propor-
tion of Behavioral Studies declined to 37% versus 63% for
Non-Behavioral Studies. Keyword selection and exclu-
sion criteria meant that not all NCDs and prevention
projects funded by the eight ICs were analyzed; instead,
the selection yielded a study sample comprising between
30% and 42% of the total number of prevention research
projects funded annually by the eight ICs (Appendix
Table 3). Of note, these are the percentage of projects
within the group of selected ICs, not the percentage of
projects that the eight ICs represented in Figure 1 based
Table 1. Average Annual Funding (FY2010–FY2012)
Behavioral Non-behavioral % behavioral
n $M SE n $M SE (Total $M)a
NCI 150 70 4.4 348 121 3.0 37
NHLBI 80 52 2.1 124 69 4.1 43
NIDDK 88 51 6.5 154 68 3.5 43
NIMH 83 30 1.1 59 28 1.4 52
NICHD 45 19 1.0 64 38 3.4 33
NIA 28 13 1.2 46 21 1.3 39
NIDA 65 27 1.2 34 14 1.0 65
NIAAA 38 15 0.8 28 11 0.7 58
Total 577 277 857 370
aProportions based on total grant amount, not total number of grants awarded.
FY, ﬁnancial year; NCI, National Cancer Institute; NHLBI, National Heart Lung and Blood Institute; NIA, National Institute on Aging; NIAAA, National
Institute on Alcohol Abuse and Alcoholism; NICHD, National Institute of Child Health Development; NIDA, National Institute on Drug Abuse; NIDDK,
National Institute of Diabetes and Digestive and Kidney Diseases; NIMH, National Institute of Mental Health; $M, million dollars.
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National Cancer Institute funded the most Behavioral
Studies in absolute dollars ($70 million annually), this
comprised only 37% of its Prevention portfolio. In
contrast, the National Institute for Drug Addiction
funded $27 million annually for Behavioral Studies,
which represented 65% of its Prevention budget—the
largest proportion of all ICs in our sample (Table 1). Based
on observed proportions, the NIH currently invests an
estimated $2.2–2.6 billion in behavioral interventions to
prevent NCDs, which comprises roughly 7%–9% of total
annual expenditures. This estimate is similar to previous
estimates of the proportion of prevention funding within
the federal research portfolio for breast cancer (10%–
11%) and the proportion of funding provided by the
National Institute of Mental Health in FY2006 to prevent
mental, emotional, and behavioral disorders in adoles-
cents (o7%).27,33
Prevention Characteristics
The majority of behavioral interventions were secondary
prevention interventions (65%), compared with primary
prevention (23%) (Table 2). Secondary prevention stud-
ies included Internet-based education for cancer screen-
ing in racial and ethnic subpopulations, cost-reduction
strategies (e.g., using lay health educators for behavioral
modiﬁcation), or Internet-based health promotion to
reduce behaviors such as college drinking. Primary
prevention strategies included changing food and phys-
ical activity policies in schools, and early childhoodeducation programs that promoted healthy eating and
physical activity from a very young age. The National
Institute for Child Health Development funded the
largest proportion of primary prevention studies (50%),
whereas the National Institute of Mental Health funded
the smallest proportion (6%) (Table 3).
Projects were overwhelmingly focused on the individ-
ual or family level (71%), compared to the population
level (22%) (Table 2), and signiﬁcant variation by IC was
observed (Table 3). Population-level approaches
included chemoprevention trials testing the efﬁcacy of
dietary supplements and web-based health promotion
interventions. The National Cancer Institute funded the
highest proportion of population-level studies (50%),
whereas the National Institute of Mental Health funded
the smallest proportion (4%) (Table 4). The majority of
behavioral interventions were delivered in multiple set-
tings (32%), which comprised clinical–community link-
ages, followed by healthcare organizations (31%)
(Table 2). The lowest percentage (2%) was observed for
workplace settings, although “workplace wellness” was
not a speciﬁc keyword search term. The percentage of
interventions delivered by technology-only platforms
(12%) was noteworthy. Few studies conducted economic
analysis (12%). Economic studies consisted mostly of
cost-effectiveness studies comparing new interventions
or policies with standard care. New interventions
included web-based programs (e.g., smoking cessation
or weight management) that augmented or replaced
intensive lifestyle modiﬁcation.www.ajpmonline.org
Table 2. Mean Distribution and Funding of Behavioral
Studies
Characteristic
Mean (FY2010–FY2012)
n $M SE %a
Type of prevention
Primary 122 64 3.1 23
Secondary 404 180 3.8 65
NA/not speciﬁed 51 33 6.9 12
Scope of prevention
Population-level 132 60 3.1 22
Individual-level 430 198 4.3 71
NA/not speciﬁed 15 20 6.5 7
Setting of prevention
Health care organization 196 86 2.8 31
Home 42 22 2.5 8
School 28 12 0.7 4
Workplace 11 5 0.3 2
Community 53 22 1.1 8
Multiple settings 161 90 6.8 32
Technology 64 32 3.2 12
NA/not speciﬁed 22 8 0.7 3
Risk factors
Mental health 104 38 1.2 14
Tobacco 41 18 0.8 6
Alcohol 23 9 0.6 3
Diet and exercise 193 114 7.2 41
Drugs 11 5 0.6 2
Multiple risk factors (2þ) 77 33 1.3 12
Other (health disparities, SES) 129 61 3.7 22
Economic analysis
Yes 62 32 1.5 12
No 457 212 7.6 76
NA/not speciﬁed 59 33 3.4 12
aMean proportion based on mean annual funding, not mean annual
number of awards
FY, ﬁnancial year; $M, million dollars; NA, not applicable.
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The highest proportion of projects investigated diet and
exercise (41%) followed by other factors (22%), mainly
social determinants of health such as SES and health
disparities (Table 2). When multiple risk factors (i.e., twoApril 2015or more risk factors, 12%) were taken into consideration,
the proportion of funding for studies by modiﬁable risk
factor broadly aligned with the current distribution of the
burden of disease in the U.S. population data as
measured by disability-adjusted life years (DALYs).6
Funding for tobacco-only studies (6%) was somewhat
low, as tobacco contributes roughly 12% to U.S. DALYs.6
Tobacco use was, however, included in the multiple–risk
factor studies. The National Institute of Drug Addiction
funded the highest proportion of multiple–risk factor
studies (52%) in the selected sample (Appendix Table 4).
When results were stratiﬁed by IC, statistically signiﬁcant
variation and clustering in funding was seen. This was
expected because ICs are structured according to speciﬁc
diseases and conditions. For example, the National
Institute on Alcohol Abuse and Alcoholism was the only
IC that funded alcohol-only studies.
Discussion
This study is the ﬁrst comprehensive descriptive analysis
of NIH funding for human behavioral interventions to
prevent six of the most costly NCDs—cancer, coronary
heart disease, hypertension, stroke, diabetes, and obesity.
Between FY2010 and FY2012, more than one third (36%)
of the NIH Prevention portfolio supported human
behavioral interventions that targeted the modiﬁable
behavioral risk factors of NCDs, whereas 63% funded
basic biomedical, animal, and genetic research. The
proportion of behavioral studies increased to 43% when
prevention projects were added that were not identiﬁed
by the current NIH algorithm.
This analysis found that the upper range of funding for
human-trial behavioral research within the prevention
portfolio (i.e., 43%) was close to the estimated 50% of
premature deaths attributed to the modiﬁable behavioral
risk factors of NCDs.6–9 The observed proportions in the
prevention research portfolio likely reﬂect the ongoing
funding priority given to basic biomedical and genomic
science. Current NIH funding for genomics far exceeds
funding for social and behavioral science, and some
researchers have argued that exaggerated expectations
and uncritical evaluations of genomic research may
divert funding from other promising approaches to
disease prevention.37 Furthermore, absolute funding for
prevention has remained stable and substantially lower
versus funding for biomedical treatments and cures
(averaging roughly 20% of total NIH expenditures
between FY2009 and FY2013).32
These funding levels do not reﬂect the opportunities
for disease prevention and health promotion to improve
population health.18 The NIH Ofﬁce of Disease Preven-
tion Strategic Plan 2014–201838 recently identiﬁed six
Table 3. Average Annual Funding (FY2010–FY2012),
by Type
Primary prevention Secondary prevention
n $M (%)a SE n $M (%)a SE
NCI 44 25 (43) 2.6 88 33 (57) 1.4
NHLBI 20 12 (26) 0.9 53 35 (74) 1.8
NIDDK 11 5 (13) 0.5 71 35 (87) 2.0
NIMH 6 2 (6) 0.3 75 27 (94) 1.1
NICHD 18 9 (50) 0.8 21 9 (50) 0.6
NIA 5 2 (16) 0.2 19 10 (84) 1.1
NIDA 13 7 (25) 0.7 51 20 (75) 0.9
NIAAA 7 3 (20) 0.3 26 11 (80) 0.6
Total 124 65 404 180
aRow percentages (primary vs secondary); therefore, column percen-
tages do not add up to 100.
FY, ﬁnancial year; NCI, National Cancer Institute; NHLBI, National
Heart Lung and Blood Institute; NIA, National Institute on Aging;
NIAAA, National Institute on Alcohol Abuse and Alcoholism; NICHD,
National Institute of Child Health Development; NIDA, National
Institute on Drug Abuse; NIDDK, National Institute of Diabetes and
Digestive and Kidney Diseases; NIMH, National Institute of Mental
Health; $M, million dollars (excludes NA/not speciﬁed); NA, not
applicable.
Table 4. Average Annual Funding (FY2010–FY2012),
by Scope
Population-level Individual-level
n $M (%)a SE n $M (%)a SE
NCI 69 31 (50) 2.8 77 32 (50) 2.1
NHLBI 15 8 (16) 0.5 62 42 (84) 2.0
NIDDK 11 5 (11) 0.5 75 38 (89) 2.0
NIMH 3 1 (4) 0.2 78 28 (96) 1.1
NICHD 10 4 (23) 0.4 32 14 (77) 0.9
NIA 9 5 (37) 0.8 19 8 (63) 0.8
NIDA 7 3 (13) 0.5 57 23 (87) 1.1
NIAAA 6 2 (13) 0.2 31 13 (87) 0.7
Total 130 59 431 198
aRow percentages (population-level vs individual-level); therefore, col-
umn percentages do not add up to 100.
FY, ﬁnancial year; NCI, National Cancer Institute; NHLBI, National Heart
Lung and Blood Institute; NIA, National Institute on Aging; NIAAA,
National Institute on Alcohol Abuse and Alcoholism; NICHD, National
Institute of Child Health Development; NIDA, National Institute on Drug
Abuse; NIDDK, National Institute of Diabetes and Digestive and Kidney
Diseases; NIMH, National Institute of Mental Health; $M, million dollars
(excludes NA/not speciﬁed); NA, not applicable.
Calitz et al / Am J Prev Med 2015;48(4):462–471468strategic priorities for national prevention research,
including developing a detailed taxonomy to systemati-
cally monitor the NIH’s investment in prevention
research and increase the visibility of prevention
research. The Strategic Plan will help to advance pre-
vention science (the systematic application of scientiﬁc
methods to the causes and prevention of diseases in
populations); however, increased levels of funding will
also be necessary to take advantage of the untapped
potential of the preventability of NCDs. We recommend
that the NIH Ofﬁce of Disease Prevention is adequately
staffed and has the necessary internal political support to
ensure that all ICs increase their support for prevention
science.
In addition to increased funding, speciﬁc knowledge
gaps also need to be addressed. Policymakers and health
ofﬁcials need credible information on the cost effective-
ness of prevention strategies in different populations and
settings in order to make informed decisions about
resource allocation. In its 2012 Report to Congress,17
the Community Preventive Services Task Force high-
lighted the importance of cost and economic outcomes as
part of determining intervention effectiveness. Our
analysis showed that only 12% of the current NIH
prevention portfolio includes economic analyses.
Although some scholars have argued that greaterinvestments in prevention may not reduce cost,19,20
policymakers want economic estimates to guide resource
allocation. According to these data, future funding
should include economic analyses where appropriate
and the NIH should collaborate with other agencies
conducting similar research to better coordinate federal
funding efforts.
This study showed that the vast majority of studies
investigated secondary prevention strategies (65%) tar-
geted at the individual or family level (71%). Several
expert scientiﬁc panels have issued recommendations
about the urgent need to test, evaluate, and scale up
evidence-based interventions directed at populations and
that seek to address both behavioral factors and improve
policies, systems, and environments.39,40 Although there
is no prescribed optimal investment level for population-
based, primary prevention of speciﬁc diseases and con-
ditions, ICs should critically assess their portfolios and
increase funding opportunities where necessary.
Reducing the burden of disease at the population level
will also require scaling up interventions that are shown
to be efﬁcacious and effective by prevention science, yet
NIH funding for dissemination and implementation
research (estimated to be $80 million between 2005 and
2012)41 is scant compared to the total dollars spent on
scientiﬁc discovery.42 Although dissemination activity is
distinct from dissemination research, testing the differentwww.ajpmonline.org
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inform practical action and is one of the identiﬁed
knowledge gaps.17,18,27 One noteworthy example in the
sample is the Diabetes Prevention Program Outcomes
Study,43 an ongoing observational study of participants
from the Diabetes Prevention Program (DPP) RCT, which
was led by the NIH and supported by CDC.44 The DPP
showed conclusively that intensive lifestyle modiﬁcation
was more effective than metformin treatment in the
prevention or delay of type 2 diabetes by reducing
progression from pre-diabetes to diabetes by 58%. The
national dissemination of the DPP is being accomplished
through the CDC-established National DPP that began in
2011.45 This coordinated endeavor brings together private
sector health insurers, third-party administrators, health-
care and community organizations such as the Young
Men’s Christian Association (YMCA), and government
agencies to widely implement DPP. In 2012, CDC
awarded $6.75 million in grants to six national organ-
izations to disseminate the program nationally. By June
2014, the YMCA’s DPP had served more than 22,300
participants at more than 940 sites in 41 states across the
country (M Longjohn, National Health Ofﬁcer, YMCA of
the U.S., personal communication, 2014). The scale-up
process currently underway demonstrates that business
models for prevention programs and services are feasible;
however, the “market for disease prevention” and the
ﬁnancial incentives necessary to create sustainable busi-
nesses are still in the early stages of development. Given
that private sector investment in promoting the wider
uptake of proﬁtable NCD prevention “products” is still
modest, we recommend that the NIH supports collabo-
rations that can help to catalyze this nascent market.
Other agencies besides the NIH are involved in
prevention science, cost effectiveness, and dissemination
and implementation research. For example, the Afford-
able Care Act mandated the creation of Patient-Centered
Outcomes Research Institute (PCORI), which is expected
to receive $3.5 billion through September 2019. PCORI
could be an important funding source to help bolster the
evidence base for cost-effective preventive interven-
tions.46 The sheer scale of NIH funding, however, results
in impacts that go well beyond knowledge creation. NIH
funding of indirect costs supports the general facility and
administrative expenses of grantees, which can approach
70%, and approximately $730 million supported training
and career development grants in FY2012.47,48 Encour-
aging skilled researchers to stay in prevention research
requires robust funding that will create sustainable career
paths, especially for junior scholars. The scale and scope
of NIH funding also affects the nature of public–pri-
vate partnerships. NIH funding for biomedicine is the
foundation of the U.S. private medical innovation sector,April 2015which generated an estimated $84 billion in wages and
$90 billion in exported goods and services in FY2011.31
The convergence of behavioral science, economics,
and new technologies is generating novel products and
systems that could help sustain behavioral change, often
a key criticism of lifestyle modiﬁcation programs. Indeed,
behavioral economics is only just starting to inﬂuence
public policy, and a growing number of interventions
using behavioral nudges, ﬁnancial incentives, and new
prevention-focused devices are showing promise in
improving patient engagement and adherence in a range
of health promotion programs.49,50 Private sector health-
care companies are responding to these market trends by
making signiﬁcant investments in digital enabling tech-
nology, spending roughly $14 billion annually—almost
half of the annual NIH budget.51 Increased federal
research in these areas would help accelerate progress
and build a stronger coalition of private sector supporters
for the NIH. Stronger consideration should be given to
implementing the NIH Ofﬁce of Disease Prevention
Strategic Plan’s objective to promote collaborations
between ICs and with external stakeholders. Establishing
private–public partnerships and working more closely
with private entities not usually engaged with the NIH
may accelerate opportunities in prevention science.52Limitations
Owing to time and resource limitations, this study did not
include all ICs, NCDs, and other funding mechanisms.
Including these additional funding mechanisms would
likely alter the proportions presented in this paper. We
opted not to make a FOIA request to obtain the current
NIH Prevention algorithm, because we were advised that
our keyword search terms were appropriate reﬂections of
the current algorithm and owing to perceived time con-
straints. Obtaining the algorithm may have simpliﬁed our
analysis; however, our ﬁndings indicate that the current
algorithm may not be capturing all prevention projects.
Finally, using the Administrative IC as the unit of analysis,
the total award amount could be captured, but it masked
interagency funding for projects. Despite these limitations,
the ﬁndings highlight a need for additional investment in
prevention science and provide a basis for future research to
delineate how U.S. federal funding portfolios are aligned
with the U.S. burden of disease and the major modiﬁable
risk factors attributed to chronic NCDs.Conclusions
Chronic underfunding for disease prevention is the result
of historic trends and persistent negative perceptions of
the value of prevention. Mayes and Oliver53 have
cogently analyzed the structural disadvantages of public
Calitz et al / Am J Prev Med 2015;48(4):462–471470health and prevention in the U.S. compared with health-
care services, which include the dispersed and delayed
beneﬁts of prevention. However, the progressive shift in
the disease burden proﬁle in the U.S. has profound
implications for the types of resources, education curric-
ula, and multisectoral partnerships that are now urgently
needed to control the rapidly rising costs of NCDs.
Investing in prevention should be a strategic national
priority to help improve the lagging population health of
the U.S. compared with other industrialized nations.14,54
The NIH should be encouraged to increase its invest-
ments in prevention science focused on reducing the
future burden of chronic diseases.
The sponsor of the study provided limited input on the study
design and had no role in the data collection, analysis, or
interpretation. The senior author (D. Yach), employed by the
sponsor of the study, contributed to the conceptualization and
writing of the report. The corresponding author (C. Calitz) had
full access to all the data in the study and had ﬁnal authority for
submission for publication. Two authors (Calitz and Millard)
conducted the research while at the Institute for Health and
Social Policy, Department of Health Policy and Management,
Bloomberg School of Public Health, Johns Hopkins University.
The opinions expressed in this paper by the lead author
(Calitz) are personal and do not reﬂect the ofﬁcial policy of
the American Heart Association. The authors thank Gerard
Anderson, PhD (Johns Hopkins University), Olakunle Alonge,
PhD (Johns Hopkins University), Carey Borkoski, PhD (Johns
Hopkins University), Melissa Antman, PhD (National Heart,
Lung, and Blood Institute, NIH), Terry Huang, PhD (Univer-
sity of Nebraska Medical Center), and Jeff Levi, PhD (Trust for
America’s Health) for their comments on earlier drafts of this
paper. The authors also thank copy editor M.L. Carter, Bowery
Consulting, New York NY.
C. Calitz and C.A. Millard received funding from The
Vitality Institute to conduct the study.
K.M. Pollack has no ﬁnancial disclosures. D. Yach owns
stock in PepsiCo and is a paid advisor to PepsiCo for health
and nutrition and Tesco’s sustainability board; he is also an
unpaid advisor to the Clinton Global Initiative and NIH’s
Fogarty Board.References
1. CDC. National Center for Chronic Disease Prevention and Health
Promotion. The power of prevention. Chronic disease: the public
health challenge of the 21st century. Atlanta, GA: CDC; 2009. www.
cdc.gov/chronicdisease/pdf/2009-Power-of-Prevention.pdf.
2. Kaiser Family Foundation. Health care costs: a primer, 2012. www.kff.
org/health-costs/report/health-care-costs-a-primer.
3. Kochanek KD, Xu J, Murphy SL, Miniño AM, Kung H. Deaths: ﬁnal
data for 2009. National Vital Statistics Reports; 2012;60(3). Hyattsville,MD: National Center for Health Statistics. www.cdc.gov/nchs/data/
nvsr/nvsr60/nvsr60_03.pdf.
4. Moses HIII , Matheson DHM, Dorsey ER, George BP, Sadoff D,
Yoshimura S. The anatomy of health care in the United States. JAMA
2013;310(18):1947–63. http://dx.doi.org/10.1001/jama.2013.281425.
5. Salomon JA, Wang H, Freeman MK, et al. Health life expectancy for
187 countries, 1990-2010: a systematic analysis for the Global Burden
Disease Study 2010. Lancet 2012;380(9859):2144–62. http://dx.doi.org/
10.1016/S0140-6736(12)61690-0.
6. U.S. Burden of Disease Collaborators. The state of U.S. health, 1990-
2010: burden of diseases, injuries, and risk factors. JAMA 2013;310(6):
591–608. http://dx.doi.org/10.1001/jama.2013.13805.
7. Mokdad AH, Marks JS, Stroup DF, Gerbeling JL. Actual causes of
death in the United States 2000. JAMA 2004;291(10):1238–45.
http://dx.doi.org/10.1001/jama.291.10.1238.
8. McGinnis MJ, Williams-Russo O, Knickman JR. The case for more
active policy attention to health promotion. Health Aff (Millwood)
2002;21(2):78–93. http://dx.doi.org/10.1377/hlthaff.21.2.78.
9. Schroeder SA. We can do better—improving the health of the
American people. N Engl J Med 2007;357:1221–8. http://dx.doi.org/
10.1056/NEJMsa073350.
10. Atkinson C, Lozano R, Naghavi M, et al. The burden of mental
disorders in the USA: new tools for comparative analysis of health
outcomes between countries. Lancet 2013;381:S10. http://dx.doi.org/
10.1016/S0140-6736(13)61264-7.
11. Murray CJL, Kulkarni SC, Michaud C, et al. Eight Americas: inves-
tigating mortality disparities across races, counties, and race-counties
in the United States. PLoS Med. 2006;3(9):e260. http://dx.doi.org/
10.1371/journal.pmed.0030260.
12. Ezzati M, Friedman A, Kulkarni SC, Murray CJL. The reversal of
fortune: trends in county mortality and cross-county mortality
disparities in the United States. PLoS Med. 2008;5(4):
e66. http://dx.doi.org/10.1371/journal.pmed.0030260.
13. Danaei G, Rimm EB, Oza S, Kulkarni SC, Murray CJL, Ezzati M. The
promise of prevention: the effects of four preventable risk factors on
national life expectancy and life expectancy disparities by race
and county in the United States. PLoS Med. 2008;7(3):
e1000248. http://dx.doi.org/10.1371/journalpmed.1000248.
14. Woolf SH, Aron LY. The U.S. health disadvantage relative to other
high-income countries: ﬁndings from a National Research Council/
Institute of Medicine report. JAMA 2013;309(8):771–2. http://dx.doi.
org/10.1001/jama.2013.91.
15. National Research Council. Scientiﬁc Opportunities and Public Needs:
Improving Priority Setting and Public Input at the National Institutes
of Health. Washington, DC: National Academies Press, 1998. www.
nap.edu/catalog.php?record_id=6225.
16. Institute of Medicine of the National Academies. Living Well With
Chronic Illness: A Call for Public Health Action. Washington, DC:
National Academies Press, 2012. www.iom.edu/Reports/2012/Living-
Well-with-Chronic-Illness.aspx.
17. Community Preventive Services Task Force. 2012 Annual Report to
Congress. 2012, Community Preventive Services Task Force. www.
thecommunityguide.org/news/2013/2012AnnualReport.html.
18. Young PL, Olsen LA. The Healthcare Imperative: Lowering Costs and
Improving Outcomes: Workshop Series Summary. Washington, DC:
National Academies Press, 2010. www.iom.edu/Reports/2011/The-Health
care-Imperative-Lowering-Costs-and-Improving-Outcomes.aspx.
19. Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save
money? Health economics and the presidential candidates. N Engl J
Med. 2008;358(7):661–3. http://dx.doi.org/10.1056/NEJMp0708558.
20. Russell LB. Preventing chronic disease: an important investment,
but don’t count on cost savings. Health Aff (Millwood) 2009;28(1):
42–5. http://dx.doi.org/10.1377/hlthaff.28.1.42.
21. Maciosek MV, Cofﬁeld AB, Flottemesch TJ, Edwards NM, Solberg LI.
Greater use of preventive services in U.S. health care could save lives at littlewww.ajpmonline.org
Calitz et al / Am J Prev Med 2015;48(4):462–471 471or no cost. Health Aff (Millwood) 2010;29(9):1656–60. http://dx.doi.org/
10.1377/hlthaff.2008.0701.
22. Teutsch SM, Fielding JE. Applying comparative effectiveness research
to public and population health initiatives. Health Aff (Millwood)
2011;30(2):349–55. http://dx.doi.org/10.1377/hlthaff.2010.0593.
23. Congressional Budget Ofﬁce. Estimating the budgetary implications
of prevention policies. Presentation at a congressional lunch brieﬁng
by Representative Michael Burgess. July 9, 2013. www.cbo.gov/
sites/default/ﬁles/cboﬁles/attachments/44420_Lunch_Brieﬁng-07_09_
13.pdf.
24. Congressional Budget Ofﬁce. Raising the excise tax on cigarettes:
effects on health and the federal budget. June 2012. www.cbo.gov/sites/
default/ﬁles/cboﬁles/attachments/06-13-Smoking_Reduction.pdf.
25. Congressional Budget Ofﬁce. Presentation on CBO’s analysis of health
care policy. Presentation to the Healthcare Leadership Council by
Douglas W. Elmendorf. January 29, 2014. www.cbo.gov/publication/
45072?utm_source=feedblitz&utm_medium=FeedBlitzEmail&utm_
content=855024&utm_campaign=0.
26. IOM. Improving Support for Health Promotion and Chronic Disease
Prevention. Washington, DC: IOM, 2014. https://www.iom.edu/~/
media/Files/Report%20Files/2010/Promoting-Cardiovascular-Health-
in-the-Developing-World/Vitality.pdf.
27. IOM. Preventing Mental, Emotional, and Behavioral Disorders Among
Young People: Progress and Possibilities. Washington, DC: National
Academies Press, 2009. www.iom.edu/Reports/2009/Preventing-Men
tal-Emotional-and-Behavioral-Disorders-Among-Young-People-Prog
ress-and-Possibilities.aspx.
28. NIH. Federal obligations for health research and development:
obligations, by federal agency. www.report.nih.gov/frrs/index.aspx.
29. Owens B. Mapping biomedical research in the USA. Lancet 2014;384
(9937):11–4. http://dx.doi.org/10.1016/S0140-6736(14)61114-4.
30. NIH. Impact: our economy. www.nih.gov/about/impact/economy.htm.
31. United for Medical Research. NIH’s role in sustaining the U.S.
economy. A 2011 updated authored by Dr. Everett Ehrlich. www.
unitedformedicalresearch.com/wp-content/uploads/2012/07/NIHs-Ro
le-in-Sustaining-the-US-Economy-2011.pdf.
32. NIH. Estimates of funding for various research, condition, and disease
categories (RCDC). www.report.nih.gov/categorical_spending.aspx.
33. National Institute of Environmental Health Sciences. Interagency
Breast Cancer and Environmental Research Coordinating Committee
(IBCERCC). Breast cancer and the environment: prioritizing preven-
tion. 2013. www.niehs.nih.gov/about/boards/ibcercc/.
34. Gross CP, Anderson GF, Powe NR. The relation between funding
by the National Institutes of Health and the burden of disease.
N Engl J Med. 1999;340(24):1881–7. http://dx.doi.org/10.1056/
NEJM199906173402406.
35. Gillum LA, Gouveia C, Dorsey ER, et al. NIH disease funding levels
and burden of disease. PLoS One 2011;6(2):e16837. http://dx.doi.org/
10.1371/journal.pone.0016837.
36. Last JM, Spasoff RA, Harris SS, eds. A Dictionary of Epidemiology, 4th
ed. New York, NY: Oxford University Press, 2000.
37. Evans JP, Meslin EM, Marteau TM, et al. Deﬂating the genomic bubble.
Science 2011;331(6091):861–2. http://dx.doi.org/10.1126/science.1198039.
38. NIH. Ofﬁce of Disease Prevention. Charting the course: the Ofﬁce of
Disease Prevention strategic plan 2014–2018. www.prevention.nih.
gov/aboutus/strategic_plan/default.aspx.
39. IOM. A population-based policy and systems change approach to
prevent and control hypertension. Washington, DC: National Aca-
demies Press, 2010.April 201540. Kumanyika SK, Obarzanek E, Stettler N, et al. Population-based prevention
of obesity: the need for comprehensive promotion of healthful eating,
physical activity, and energy balance: a scientiﬁc statement from American
Heart Association Council on Epidemiology and Prevention, Interdiscipli-
nary Committee for Prevention (formerly the Expert Panel on Population
and Prevention Science). Circulation 2008;118(4):428–64. http://dx.doi.org/
10.1161/CIRCULATIONAHA.108.189702.
41. Tinkle M, Kimball R, Haozous EA, Shuster G, Meize-Grochowski R.
Dissemination and implementation research funded by the U.S.
National Institutes of Health, 2005–2012. Nurs Res Pract. 2013;2013:
909606. http://dx.doi.org/10.1155/2013/909606.
42. Glasgow RE, Vinson C, Chambers D, Khoury MJ, Kaplan RM, Hunter C.
National Institutes of Health approaches to dissemination and implementa-
tion science: current and future directions. Am J Public Health. 2012;102(7):
1274–81. http://dx.doi.org/10.2105/AJPH.2012.300755.
43. Diabetes Prevention Program Research Group. 10-year follow-up of
diabetes incidence and weight loss in the Diabetes Prevention Program
Outcomes Study. Lancet 2009;374(9702):1677–86. http://dx.doi.org/
10.1016/S01406736(09)61457-4.
44. Diabetes Prevention Program Research Group. Reduction in the incidence
of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med.
2002;346(6):393–403. http://dx.doi.org/10.1056/NEJMoa012512.
45. CDC. National Diabetes Prevention Program. www.cdc.gov/diabetes/
prevention/about.htm.
46. Patient Centered Outcomes Research Center. www.pcori.org/about-us/
landing.
47. GAO Report. Biomedical research. NIH should assess the impact of
growth in indirect costs on its mission. September 2013. www.gao.gov/
assets/660/658087.pdf.
48. NIH. Research Portfolio Online Reporting Tools. Funding facts. www.
report.nih.gov/fundingfacts/fundingfacts.aspx.
49. Loewenstein G, Asch DA, Volpp KG. Behavioral economics holds
potential to deliver better results for patients, insurers, and employers.
Health Aff (Milwood) 2013;32(7):1244–50. http://dx.doi.org/10.1377/
hlthaff.2012.1163.
50. Asch DA, Muller RW, Volpp KG. Automated hovering in health care:
watching over the 5000 overs. N Engl J Med. 2012;367(1):
1–3. http://dx.doi.org/10.1056/NEJMp1203869.
51. Jaruzelski B, Loehr J. The Global innovation 1000. Navigating the digital
future. Booz & Co Strategy and Business 2013;73(Winter 2013):32–45.
52. Yach D, Calitz C. New opportunities in the changing landscape of
prevention. JAMA 2014;312(8):791–2. http://dx.doi.org/10.1001/
jama.2014.8900.
53. Mayes R, Oliver TR. Chronic disease and the shifting focus of public
health: is prevention still a political lightweight. J Health Polit Policy
Law. 2012;37(2):181–201. http://dx.doi.org/10.1215/03616878-153593.
54. Vitality Institute Commission Report. Investing in prevention: a
national imperative. Key ﬁndings and recommendations from the
Vitality Institute Commission on Health Promotion and the Preven-
tion of Chronic Disease in Working-Age Americans. www.thevitali
tyinstitute.org/commission.Appendix
Supplementary Data
Supplementary data associated with this article can be found at
http://dx.doi.org/10.1016/j.amepre.2014.10.015.
